Inactive Instrument

Pharmiva AB (publ)

PHARM

SE0015530670

Equity Research, Pharmiva: Merger with Peptonic could spark the fire

August 23, 2023 at 06:03 am EDT

Carlsquare Equity Research comments on the approval by the EGM to approve the merger with Peptonic.

Read the full comment here.

About Carlsquare

Carlsquare is a global research firm and financial advisor, focusing on M&A, Equity
Research and Growth Equity. Carlsquare has 150 employees with deep sector knowledge in all 11
GICS sectors. The senior equity research team has extensive experience about the stock
environment and several business sectors. The team produces company research reports,
independent valuations and trading notes. The group have offices in Berlin, Copenhagen,
Frankfurt, Hamburg, London, Munich, Paris, San Francisco and Stockholm. Read more

Contact
MARKUS AUGUSTSSON
Head of Equity Research
markus.augustsson@carlsquare.com
+46 (0)76 235 03 20

Latest news about Pharmiva AB (publ)

PEPTONIC medical AB completed the acquisition of Pharmiva AB (OM : PHARM).	Nov. 20	CI
Walmart Starts Selling Peptonic's Products in the US	23-10-10	CI
Pharmiva Accepts Peptonic Merger for Creation of Global Femtech Company	23-08-21	MT
Pharmiva AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-16	CI
Women’s Health Companies Peptonic, Pharmiva to Merge	23-06-15	MT
Pharmiva AB (OM:PHARM) entered in the letter of intent to acquire PEPTONIC medical AB.	23-06-14	CI
Pharmiva AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-24	CI
Pharmiva AB Auditor Raises 'Going Concern' Doubt	23-04-19	CI
1,317,516 Shares of Pharmiva AB are subject to a Lock-Up Agreement Ending on 25-MAR-2023.	23-03-24	CI
Pharmiva AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-02-22	CI
Pharmiva AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-16	CI
Pharmiva AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-17	CI
Pharmiva AB Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-11	CI
Pharmiva AB announced that it has received SEK 1.2 million in funding	22-04-11	CI
Pharmiva AB has completed an IPO in the amount of SEK 35 million.	21-03-31	CI
Pharmiva AB has filed an IPO.	21-03-04	CI

Chart Pharmiva AB (publ)

Duration

Period

More charts

Company Profile

Pharmiva AB (publ) is a Sweden-based medical technology company within FemTech that is focused on research and development of medical products. Pharmiva AB (publ) aims to improve vaginal health and reduce the risk of complications by offering treatments without antibiotics. The company's first product Vernivia is antibiotic- and prescription-free treatment for bacterial vaginosis (BV). The treatment is based on Pharmiva AB's (publ) patented drug delivery platform, Venerol, which contains naturally occurring ingredients. The company has received CE marking class IIa for Vernivia, which means that Pharmiva AB (publ) has the right to sell and market the product within the EEA. Pharmiva AB (publ) is also ISO-certified according to ISO 13485 current design, production, marketing and sales.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals